Aphria Inc. logo
Aphria Inc. APHA

Aphria Inc. Financial Ratios 2011-2026 | APHA

Annual Financial Ratios Aphria Inc.

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-13.1 -103.1 50.9 101.9 174.3 -5.8 - - - -

P/S

2.0 7.2 40.6 20.9 8.2 68.3 - - - -

EV/EBITDA

-117.4 -25.3 71.3 124.4 -72.6 -4.6 - - - -

PEG

-0.03 0.75 0.15 0.34 -1.63 0.1 - - - -

P/B

0.6 1.0 1.3 1.6 2.0 2.8 - - - -

P/CF

-4.2 -6.5 -6.7 -6.9 -12.7 -4.7 - - - -

ROE %

-4.60 -0.95 2.51 1.53 1.14 -49.03 - - - -

ROA %

-3.39 -0.68 2.24 1.33 1.10 -45.78 - - - -

ROCE %

-2.49 -3.81 1.10 0.69 -3.11 -50.01 - - - -

DSO

55.2 133.2 177.9 103.6 107.0 731.9 - - - -

DIO

206.8 165.1 418.2 451.7 310.4 -2585.4 - - - -

DPO

119.5 190.9 595.1 682.5 188.2 -1420.3 - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Aphria Inc., allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 8.97 2.87 % $ 88.7 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.66 - $ 8.81 B australiaAustralia
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
$ 3.21 3.05 % $ 274 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 95.59 -1.15 % $ 27.2 B germanyGermany
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Burford Capital Limited Burford Capital Limited
BUR
$ 4.68 4.23 % $ 746 M britainBritain
Cabaletta Bio Cabaletta Bio
CABA
$ 3.27 2.19 % $ 329 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 21.46 0.47 % $ 1 B usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.49 1.35 % $ 383 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.03 3.77 % $ 4.99 M israelIsrael
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.19 - $ 448 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 24.98 3.55 % $ 3.18 B usaUSA
Chimerix Chimerix
CMRX
- - $ 756 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 32.74 0.46 % $ 2.17 B usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.48 0.46 % $ 394 M britainBritain
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
CNS Pharmaceuticals CNS Pharmaceuticals
CNSP
$ 2.44 -2.99 % $ 1.08 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany